Repositioning Candidate Details
| Candidate ID: | R1407 |
| Source ID: | DB11811 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Arhalofenate |
| Synonyms: | Arhalofenate |
| Molecular Formula: | C19H17ClF3NO4 |
| SMILES: | CC(=O)NCCOC(=O)[C@H](OC1=CC=CC(=C1)C(F)(F)F)C1=CC=C(Cl)C=C1 |
| Structure: |
|
| DrugBank Description: | Arhalofenate has been investigated for the treatment of Gout and Hyperuricemia. |
| CAS Number: | 24136-23-0 |
| Molecular Weight: | 415.79 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Partial agonist of peroxisome proliferator-activated receptor (PPAR) gamma; results in improved glucose, lipid, and weight management. |
| Targets: | Peroxisome proliferator-activated receptor gamma |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |